These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38889339)

  • 1. Co-delivery Nano System of MS-275 and V-9302 Induces Pyroptosis and Enhances Anti-Tumor Immunity Against Uveal Melanoma.
    Ren H; Wu Z; Tan J; Tao H; Zou W; Cao Z; Wen B; Cai Z; Du J; Deng Z
    Adv Sci (Weinh); 2024 Aug; 11(31):e2404375. PubMed ID: 38889339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microenvironment-Responsive Prodrug-Induced Pyroptosis Boosts Cancer Immunotherapy.
    Xiao Y; Zhang T; Ma X; Yang QC; Yang LL; Yang SC; Liang M; Xu Z; Sun ZJ
    Adv Sci (Weinh); 2021 Dec; 8(24):e2101840. PubMed ID: 34705343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC inhibitor regulates the tumor immune microenvironment via pyroptosis in triple negative breast cancer.
    Yang X; Cui X; Wang G; Zhou M; Wu Y; Du Y; Li X; Xu T
    Mol Carcinog; 2024 Sep; 63(9):1800-1813. PubMed ID: 38860600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma.
    Venza M; Visalli M; Oteri R; Agliano F; Morabito S; Teti D; Venza I
    Int Immunopharmacol; 2015 Sep; 28(1):313-21. PubMed ID: 26122536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
    Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
    Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
    Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
    BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Cell Death-Related Gene Signature Associated with Prognosis and Immune Infiltration and the Roles of HMOX1 in the Proliferation and Apoptosis were Investigated in Uveal Melanoma.
    Zhao Y; Wang L; Li X; Jiang J; Ma Y; Guo S; Zhou J; Li Y
    Genes Genomics; 2024 Jul; 46(7):785-801. PubMed ID: 38767825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
    Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-Responsive Supramolecular Polymeric Nanomedicine for Self-Cascade Amplified Cancer Immunotherapy.
    Hu W; Ye B; Yu G; Yang H; Wu H; Ding Y; Huang F; Wang W; Mao Z
    Adv Sci (Weinh); 2024 May; 11(20):e2305382. PubMed ID: 38493499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
    Moschos MM; Dettoraki M; Androudi S; Kalogeropoulos D; Lavaris A; Garmpis N; Damaskos C; Garmpi A; Tsatsos M
    Anticancer Res; 2018 Jul; 38(7):3817-3824. PubMed ID: 29970501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum adsorption, cellular internalization and consequent impact of cuprous oxide nanoparticles on uveal melanoma cells: implications for cancer therapy.
    Song H; Xu Q; Zhu Y; Zhu S; Tang H; Wang Y; Ren H; Zhao P; Qi Z; Zhao S
    Nanomedicine (Lond); 2015; 10(24):3547-62. PubMed ID: 26467678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entinostat induces antitumor immune responses through immune editing of tumor neoantigens.
    Truong AS; Zhou M; Krishnan B; Utsumi T; Manocha U; Stewart KG; Beck W; Rose TL; Milowsky MI; He X; Smith CC; Bixby LM; Perou CM; Wobker SE; Bailey ST; Vincent BG; Kim WY
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma.
    Dai W; Zhou J; Jin B; Pan J
    Sci Rep; 2016 Mar; 6():22622. PubMed ID: 26940009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC Inhibition Enhances the
    Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
    Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade.
    Ruan H; Hu Q; Wen D; Chen Q; Chen G; Lu Y; Wang J; Cheng H; Lu W; Gu Z
    Adv Mater; 2019 Apr; 31(17):e1806957. PubMed ID: 30856290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Cascade Polydopamine Nanoclusters for Pyroptosis-Based Tumor Immunotherapy.
    Han Z; Liang Y; Li Y; Yuan M; Zhan X; Yan J; Sun Y; Luo K; Zhao B; Li F
    Small; 2024 Oct; 20(42):e2401397. PubMed ID: 38898735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP.
    Venza I; Visalli M; Oteri R; Teti D; Venza M
    Int Immunopharmacol; 2014 Aug; 21(2):439-46. PubMed ID: 24946096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of Melanoma.
    Wang S; Guo Q; Xu R; Lin P; Deng G; Xia X
    J Nanobiotechnology; 2023 Oct; 21(1):383. PubMed ID: 37858186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.